RedHill Biopharma (RDHL) Registration Filing summary

Company overview and business model

• Specialty biopharmaceutical company focused on gastrointestinal (GI) and infectious diseases, aiming to become a leading player in this space.

• Commercializes GI-related products in the U.S., including Talicia® and, until October 8, 2024, Aemcolo®; pipeline includes five clinical-stage therapeutic candidates.

• Pursues a strategy of in-licensing, acquiring, and developing products with high therapeutic and commercial potential, with commercialization plans involving licensing, partnerships, or independent operations.

• Recently terminated the U.S. license for Aemcolo® and signed a Global Termination Agreement, resulting in a net balance sheet reduction and restored control over Talicia® cash flows.

Financial performance and metrics

• As of August 9, 2024, aggregate market value of outstanding equity held by non-affiliates was approximately $24.2 million, based on 32,013,477 ADSs at $0.76 per ADS.

• January 2024 offering raised gross proceeds of approximately $7.1 million; April 2024 offering raised approximately $1.2 million.

• Pro forma total capitalization as of December 31, 2023, was $31.3 million, including $29.9 million in total debt and $1.4 million in shareholders' equity.

• Financial statements include a going concern reference and adverse opinion on internal control effectiveness.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, R&D for therapeutic candidates, potential acquisitions, and to support commercial operations.